PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-2.79%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
1.20%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.99%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
3.80%
Share count expansion well above AVXL's 0.69%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.10%
Diluted share count expanding well above AVXL's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
35.18%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
35.60%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13691.29%
Negative 10Y OCF/share CAGR while AVXL stands at 42.37%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
29.84%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
58.26%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-7976.92%
Negative 10Y net income/share CAGR while AVXL is at 69.61%. Joel Greenblatt sees a major red flag in long-term profit erosion.
76.35%
5Y net income/share CAGR 1.25-1.5x AVXL's 60.10%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
62.71%
3Y net income/share CAGR above 1.5x AVXL's 19.29%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1259.19%
10Y equity/share CAGR above 1.5x AVXL's 197.16%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
224.33%
5Y equity/share CAGR at 75-90% of AVXL's 271.24%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
-84.52%
Negative 3Y equity/share growth while AVXL is at 19.38%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.68%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D dropping or stable vs. AVXL's 47.03%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-32.93%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.